The Journal for ImmunoTherapy of Cancer
is an open access journal that publishes high quality research, literature reviews, position papers and practice guidelines, and case studies on all components of cancer immunology and immunotherapy.
Impact Factor: 12.485
Citescore: 14.3
All metrics >>
Highlighted Articles
Imaging and Immunotherapy
Review:
Artificial intelligence and radiomics: fundamentals, applications, and challenges in immunotherapy30 September 2022
Review:
Imaging cellular immunotherapies and immune cell biomarkers: from preclinical studies to patients22 September 2022
Latest Articles
Oncolytic and local immunotherapy:
Adaptation of transgene mRNA translation boosts the anticancer efficacy of oncolytic HSV123 March 2023
Clinical/translational cancer immunotherapy:
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)22 March 2023
Clinical/translational cancer immunotherapy:
First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC)22 March 2023
Clinical/translational cancer immunotherapy:
Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)22 March 2023
Most Read Articles
Clinical/translational cancer immunotherapy:
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, sing…21 January 2022
Immunotherapy biomarkers:
Therapeutic targeting of PD-1/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment21 July 2022
Position article and guidelines:
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events25 June 2021
Altmetrics
What Our Editors Are Reading
In JITC’s Reading List, JITC editors provide a monthly list of publications in other journals that have their attention and add value to what readers may find in JITC. Read what has piqued the interest of this month’s featured editor in the latest Reading List.
About SITC
The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. As a way to thank the SITC members who work tirelessly to advance the science and improve the lives of cancer patients, SITC provides members with a 35% discount on Article Processing Charges (APCs) for all JITC articles submitted and accepted in 2023. This discount is applied post-acceptance, at which point a discount code is shared with the corresponding author.
For information on APC discounts and waivers – including those for members, editors or reviewers, low-income countries, or institutional arrangements – view the journal's APC policy.